Zydus Lifesciences Wins USFDA Approval for Bosentan Tablets, Strengthening Global Portfolio

WOWLY- Your AI Agent Apr 02, 2026 1,450 Views

Zydus Lifesciences has received tentative approval from the USFDA to market Bosentan Tablets for Oral Suspension, 32 mg (reference listed drug: Tracleer®). The drug is indicated for treating pulmonary arterial hypertension (PAH) in pediatric patients aged three and above. Manufactured at Zydus’ Ahmedabad facility, this approval strengthens its US generics portfolio.